IBJNews

Lilly says its once-daily insulin tops competitor's drug

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly & Co. said its experimental insulin helped diabetic patients more than Sanofi’s biggest product in studies that also raised some safety risks.

Lilly’s once-a-day insulin injection was better than Sanofi’s Lantus in controlling patients’ blood sugar, a measure of how well a patients’ diabetes is under control.

Indianapolis-based Lilly said it will file for U.S. approval to sell the drug in the first quarter of next year.

The three studies showed increases in rates of liver enzymes, a potential sign of toxicity, and lower rates of good, or HDL, cholesterol, safety issues that may give Lilly a hard time when selling the drug, said Mark Schoenebaum, an analyst with ISI Group LLC. U.S. regulators may also require another trial before they will grant approval, he said.

“We are reasonably bearish on this molecule due to potential toxicity concerns,” Schoenebaum wrote in an e-mail. Annual sales of the drug may be about $600 million by 2020 if it is approved, he said.

Lantus generated $7.59 billion for Paris-based Sanofi last year. The medicine’s sales are projected by analysts to increase to at least $10 billion in 2016, according to estimates compiled by Bloomberg.

Lilly rose were up 18 cents Monday morning, to $59.51. Sanofi rose 1.5 percent.

Lilly has made an aggressive push to expand its diabetes products, with drugs in every class of therapy for what it calls a full suite of offerings for doctors, health insurers and governments.

In three trials including 3,373 patients, Lilly’s insulin was superior to Lantus in controlling blood sugar. It was tested in patients who’d never used an insulin before, those switching over from another insulin, and in combination with a shorter-acting insulin meant to control blood sugar after meals.

Lilly’s drug “is the first basal insulin to demonstrate consistently superior HbA1c reduction versus insulin glargine in Phase III clinical trials,” Enrique Conterno, president of Lilly’s diabetes business, said in a statement announcing the trial results. Lilly will release full results of the trial, which is continuing, later this year.

Basal insulins are designed to be a baseline of blood sugar control. They’re often given with other medications to control elevated blood sugar after meals. The trials tested Lilly’s drug in combination with those drugs and on its own.

In the U.S., 25.8 million people have diabetes, about 8 percent of the population, according to the American Diabetes Association. The adult form of the disease is often driven by obesity, and is projected to grow as American waistlines continue to expand.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Can your dog sign a marriage license or personally state that he wishes to join you in a legal union? If not then no, you cannot marry him. When you teach him to read, write, and speak a discernible language, then maybe you'll have a reasonable argument. Thanks for playing!

  2. Look no further than Mike Rowe, the former host of dirty jobs, who was also a classically trained singer.

  3. Current law states income taxes are paid to the county of residence not county of income source. The most likely scenario would be some alteration of the income tax distribution formula so money earned in Marion co. would go to Marion Co by residents of other counties would partially be distributed to Marion co. as opposed to now where the entirety is held by the resident's county.

  4. This is more same-old, same-old from a new generation of non-progressive 'progressives and fear mongers. One only needs to look at the economic havoc being experienced in California to understand the effect of drought on economies and people's lives. The same mindset in California turned a blind eye to the growth of population and water needs in California, defeating proposal after proposal to build reservoirs, improve water storage and delivery infrastructure...and the price now being paid for putting the demands of a raucous minority ahead of the needs of many. Some people never, never learn..

  5. I wonder if I can marry him too? Considering we are both males, wouldn't that be a same sex marriage as well? If they don't honor it, I'll scream discrimination just like all these people have....

ADVERTISEMENT